Lallemand Pharma International (LPI) is a pharmaceutical subsidiary of the Lallemand group. LPI is in charge of the business and possesses the intellectual property rights of an immunostimulant drug  indicated in the prevention of respiratory infections known as Polyvalent Mechanical Bacterial Lysate (PMBL) tablets.

Lallemand Pharma AG, subsidiary of LPI, is dedicated exclusively to the clinical studies, registrations, marketing and sales of this PMBL drug. The original PMBL active pharmaceutical ingredient is produced by the Lallemand GMP Pharma facility.

Thanks to its important distributor’s network consisting of leading international pharmaceutical companies, the core business of Lallemand Pharma is to develop and market all around the world drugs containing PMBL under different brands: Ismigen®, Immubron®, Respibron®, PIR-05®, Provax®, and Pulmigen®